JAK3 and graft versus host disease: The JAK3 inhibitor Tofacitinib (CP-690550) was reported to ameliorate GVHD in vivo and in vitro by selectively inhibiting Th1 differentiation but not Th17 polarization or CD4 T cell proliferation (183).